ArticlePloS one2017
Acinetobacter baumannii strains isolated from patients in intensive care units in Goiânia, Brazil: Molecular and drug susceptibility profiles.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Antimicrobial resistance pattern of Acinetobacter baumannii clinical isolate in Ethiopia. A systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Prevalence of biofilm producing Acinetobacter baumannii clinical isolates: A systematic review and meta-analysis.PloS one · 2023Pooled it
- Outbreak of Multidrug-Resistant (MDR) Acinetobacter baumannii ST-15 Strains Co-producing OXA-23 and OXA-58 in South America.Current microbiology · 2026Article
- Daily rhythms modulate Acinetobacter baumannii physiology impacting infection outcome and antibiotic-inactivating capacity.Scientific reports · 2026Article
- Burden and resistance of Gram-negative pathogens in ICU-acquired infections in Vietnam: a cross-sectional study.Iranian journal of microbiology · 2026Article
- Characteristics of Bacterial Isolates from Patients with Ventilator-Associated Pneumonia and the Hospital Environment in Urmia, Iran.Tanaffos · 2025Article
- A chionodracine-derived peptide, KHS-Cnd, as an anti-virulence agent against multidrug-resistantFrontiers in cellular and infection microbiology · 2025Article
- New antibacterial candidates against Acinetobacter baumannii discovered by in silico-driven chemogenomics repurposing.PloS one · 2024Article
- Using an Aluminum Hydroxide-Chitosan Matrix Increased the Vaccine Potential and Immune Response of Mice against Multi-Drug-ResistantVaccines · 2023Article
- The Prevalence of Virulence Factor Genes among Carbapenem-Non-SusceptibleDiagnostics (Basel, Switzerland) · 2023Article
- Biosurfactant from Nile Papyrus endophyte with potential antibiofilm activity against global clones ofFrontiers in cellular and infection microbiology · 2023Article
- Article
- Molecular Characterization Identifies Upstream Presence of ISJournal of laboratory physicians · 2022Article
- Molecular Detection of Drug-Resistance Genes ofMicroorganisms · 2021Article
- Polymyxin Resistance Among XDR ST1 Carbapenem-ResistantFrontiers in microbiology · 2021Article
- Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU.BMC infectious diseases · 2020Article
- Genotyping and molecular characterization of clinicalPathogens and global health · 2020Article
- Molecular typing of multi-drug resistant Acinetobacter baumannii isolates from clinical and environmental specimens in three Iranian hospitals by pulsed field gel electrophoresis.BMC microbiology · 2020Article
- Molecular epidemiology and drug resistance of Acinetobacter baumannii isolated from a regional hospital in the Brazilian Amazon region.Revista da Sociedade Brasileira de Medicina Tropical · 2020Article
- Multidrug-resistant Acinetobacter baumannii outbreaks: a global problem in healthcare settings.Revista da Sociedade Brasileira de Medicina Tropical · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to antimicrobial agents is increasing worldwide and imposes significant life-threatening risks to several different populations, especially those in intensive care units (ICUs). Bacteria can quickly develop or acquire resistance to antimicrobial drugs, and combined with their intrinsic potential to cause disease in humans, these bacteria can become deadly. Among Gram-negative bacteria, Acinetobacter baumannii is notorious as a frequent opportunistic pathogen associated with critically ill patients, and understanding the genetic basis of A. baumannii resistance to beta-lactams among patients in ICUs will result in better protocols to prevent the development of resistance as well as improved treatment regimens. In this study, we assessed 1333 patients in five ICUs, 56 of whom developed A. baumannii infections. Most of the A. baumannii isolates were resistant to beta-lactam antimicrobial drugs, specifically, 3rd- and 4th-generation cephalosporins and carbapenems, and 91.1% of the isolates were multi-drug resistant (MDR). The most frequent OXA gene present was OXA-23 (55.1%), which is significantly associated with MDR strains. Most of the A. baumannii isolates (76.8%) were capable of forming a biofilm. The antimicrobial drug classes that were effective against most of these isolates were polymyxins and tigecycline. The molecular profile of the isolates allowed detection of 12 different clusters comprising 2 to 8 isolates each. In conclusion, our data indicate a high incidence of resistance to carbapenems as well as MDR strains among the observed A. baumannii isolates, most of which exhibited a high prevalence of OXA-23 gene expression. Only a few selective drugs were effective, reinforcing the notion that bacterial resistance is an emerging problem that should be prioritized in every healthcare facility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.